Navigation Links
New therapeutic target for prostate cancer identified

New Rochelle, NY, July 16, 2012A small, naturally occurring nucleic acid sequence, called a microRNA, known to regulate a number of different cancers, appears to alter the activity of the androgen receptor, which plays a critical role in prostate cancer. Directly targeting microRNA-125b to block androgen receptor activity represents a novel approach for treating castrate-resistant prostate cancer. This promising new strategy for improving the effectiveness of anti-androgenic and other hormonal therapies is described in an article in BioResearch Open Access, a new bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc.. The article is available free online at the BioResearch Open Access website.

Prostate cancer is the most common non-skin cancer affecting men and the second most common cause of cancer death among men. In the article "miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2," Xiaoping Yang, Lynne Bernis, Lih-Jen Su, Dexiang Gao, and Thomas Flaig, University of Colorado Denver (Aurora) and University of Minnesota (Duluth), looked for targets of microRNA-125b that might shed light on its role in regulating prostate cancer and found that it directly inhibits NCOR2, which acts to repress the androgen receptor. The authors point out that "the androgen receptor is a critical therapeutic target in prostate cancer" and that alterations in the receptor are essential for the development of castrate-resistant prostate cancer, in which the disease no longer responds to hormonal therapies.

"This research provides new insight into the mechanism of miR-125b regulation of castrate-resistance prostate cancer through the identification of a novel target for miR-125b," says Editor-in-Chief Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland. "The clinical implications of this study are that targeted regulation of this miRNA may lead to more effective anticancer therapies."


Contact: Vicki Cohn
914-740-2100 x2156
Mary Ann Liebert, Inc./Genetic Engineering News

Related biology news :

1. Magical state of embryonic stem cells may help overcome hurdles to therapeutics
2. Understanding the RNAi Reagents Market Overlap with Drug Discovery and Therapeutic Development is Critical for Pharmaceutical Leaders
3. 2 Cell Transplantation studies impact dental stem cell research for therapeutic purposes
4. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
5. Scientists identify FLT3 gene as a valid therapeutic target in acute myeloid leukemia
6. UofL research holds promise of therapeutic approach for gum disease
7. AnaptysBio Adds Dr. David L. Lacey and Dr. Michael Gallatin to Therapeutic Advisory Board
8. Cancer Cell article shows first evidence for targeting of Pol I as new approach to cancer therapy
9. Developing world has less than 5 percent chance of meeting UN child hunger target, study estimates
10. Innate immune system protein provides a new target in war against bacterial infections
11. Antitoxin strategy may help target other pathogens
Post Your Comments:
Related Image:
New therapeutic target for prostate cancer identified
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/9/2015)... Nov. 09, 2015 ... of the "Global Law Enforcement Biometrics ... --> ) has announced ... Enforcement Biometrics Market 2015-2019" report to ... Markets ( ) has announced the ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... CHESTERFIELD, United Kingdom , Nov. 27, 2015 /PRNewswire/--  ... specialty biopharmaceutical company, announced today that it has closed ... systems (CMDS) business to Guerbet (GBT- NYSE Euronext) in ... CMDS operations encompassed four manufacturing facilities and a total ... nearly 75 in the St. Louis ...
(Date:11/27/2015)... 27, 2015 ... of companion diagnostics is one of the ... with pharmaceutical companies and diagnostic manufacturers working ... . --> ... on global cancer biomarkers market spread across ...
(Date:11/26/2015)... , November 26, 2015 --> ... company specializing in imaging technologies, announced today that it has ... part of the Horizon 2020 European Union Framework Programme for ... large-scale clinical trial in breast cancer. , ... --> --> The study ...
(Date:11/25/2015)...  PharmAthene, Inc. (NYSE MKT: PIP) announced  today that ... plan (Rights Plan) in an effort to preserve the ... Section 382 of the Internal Revenue Code (Code). ... of its NOLs could be substantially limited if the ... 382 of the Code. In general, an ownership change ...
Breaking Biology Technology: